Sage Therapeutics Inc (FRA:SG7)
€ 5.452 0.102 (1.91%) Market Cap: 325.18 Mil Enterprise Value: -211.07 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 49/100

Sage Therapeutics, Inc. - Special Call Transcript

Jul 24, 2019 / 12:00PM GMT
Release Date Price: €159.98 (-0.20%)
Maren Killackey
Sage Therapeutics, Inc. - Senior Analyst of Inventor Relation

Good morning, and thank you for joining the Sage FutureCast Call.

Before we begin, I encourage everyone to go to the Investors & Media section of our website at sagerx.com, where you can find the press release related to today's call as well as the slides that we will discuss.

I would like to point out that we will be making forward-looking statements, which are based on current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please consult the risk factors discussed in today's press release and our SEC filings for additional details.

We will begin the call with prepared remarks by Dr. Jeff Jonas, our Chief Executive Officer; Dr. Jim Doherty, our Chief Research Officer; Dr. Rob Lasser, Vice President Late-Stage Development; Dr. Helen Colquhoun, Vice President Early Development; and Dr. Aaron Koenig, Medical Director Early Development. We will be joined for the Q&A session of the call by Kimi Iguchi, our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot